Pharmacokinetics of Heparin in Healthy and Obese Subjects and in Combination with Dihydroergotamine

Summary

Heparin (5000 IE s.c., 5000 IE i v, 200 IE/kg i v) was given to healthy volunteers without and with 0.5 mg dihydroergotamine (DHE) i v to test whether DHE influences the kinetics of heparin. The anticoagulant (200 IE/kg) was also administered to obese subjects. Heparin was assayed using a chromogenic substrate for activated factor X.

The plasma levels of heparin did not differ whether given concomitantly with DHE or not. Halflife of heparin was also uninfluenced of DHE demonstrating that the beneficial effect of DHE on postoperative thromboembolism is not caused by interaction with the pharmacokinetics of heparin.

The plasma levels of heparin were significantly higher in the obese subjects than in the normal ones. The halflife of the drug averaged 2.13 h in the obese subjects and 1.36 h in the normal subjects (p<0.02). It was concluded that the heparin dosage should be calculated in terms of estimated ideal weight.

Keywords

Dihydroergotamine - Drug interaction - Heparin - Thromboembolism

• References

• 1 McAvoy TJ. The biologic halflife of heparin. Clin Pharm Ther 1979; a; 25: 372-379
• 2 Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin. Acta Med Scand 1963; 173: 619-630
• 3 McAvoy TJ. Pharmacokinetic Modeling of Heparin and Its Clinical Implications. J Pharmacokinet Biopharm 1979; b; 7: 331-354
• 4 Kakkar VV, Corrigan TP, Fossard DP. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: An international multicentre trial. Lancet 1975; ii: 45-51
• 5 Lahnborg G, Bergström K, Friman L, Lagergren H. Effect of lowdose heparin on incidence of postoperative pulmonary embolism detected by photoscanning. Lancet 1974; i: 329-331
• 6 Nicolaides AN, Dupont PA, Desai S, Lewis JD, Douglas JN, Dodsworth H, Fourides G, Luck RJ, Jamieson CW. Small doses of subcutaneous sodium heparin in preventing deep venous thrombosis after major surgery. Lancet 1972; ii: 890-893
• 7 Butterman G, Theisinger W, Weidenbach A, Hartung R, Welzel D, Pabst HW. Quantitative Bewertung der postoperativen Thromboembolieprophylaxe. Med Klin 1977; 72: 1624-1638
• 8 Koppenhagen K, Wiechmann A, Frey E, Wenig HD, Latka H, Zuhlke HU, Tank E, Hardieck J, Ernst H, Häring R. Klinisch experimentelle Ergebnisse mit Heparin-Dihydroergotamin. Dtsch med Wschr 1977; 39: 1374-1378
• 9 Sagar S, Nairn D, Stamatakis JD, Maffei FH, Higgins AF, Thomas DP, Kakkar VV. Efficacy of low-dose heparin in prevention of extensive deep vein thrombosis in patients undergoing total-hip replacement. Lancet 1976; i: 1151-1154
• 10 Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrats for activated factor X. Thromb Res 1976; 8: 413-416
• 11 Kunz S. Das Thromboserisiko nach abdominaler und vaginaler Hysterektomie. Geburtsh und Frauenheilk 1979; 39: 932-939
• 12 Mellander S, Nordenfelt I. Comparative effects of dihydroergotamine and noradrenaline on resistance, exchange and capitance functions in the peripheral circulation. Clin Sci 1970; 39: 183-201
• 13 Stamatakis JD, Kakkar VV, Lawrence D, Wars VP. Synergistic effect of heparin and dihydroergotamine in the prophylaxis of deep vein thrombosis In Postoperative Thromboembolie-Prophylaxe. 1977. p 109-118 Ed von H wPabst, Maureu G. Schattauer; Stuttgart: